AtriCure to Present at the UBS Global Healthcare Conference
Get Alerts ATRC Hot Sheet
Join SI Premium – FREE
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip left atrial appendage management (LAAM) exclusion device is the most widely sold device worldwide that is indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. AtriCure recently acquired nContact, a leader in minimally invasive technology for epicardial ablation. nContact’s mission is to transform the underserved arrhythmia population through a multidisciplinary epicardial-endocardial ablation approach. Afib affects more than 33 million people worldwide. For more information visit AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160502006040/en/
AtriCure, Inc.
Andy Wade
Senior Vice President and
Chief Financial Officer
513-755-4564
[email protected]
or
Investor
Relations
Gilmartin Group
Lynn Pieper
415-937-5402
[email protected]
Source: AtriCure, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- King Risk Partners Expands New York Presence with Norton and Siegel
- Three Cleveland Krist Attorneys Recognized by Best Lawyers for 2027
- TraceLink MINT Transaction Volume in 2026 Surpasses Full-Year 2025 Volume by 183% as Customers Expand Digital Supply Chain Collaboration
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
UBS, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share